What is the appropriate evaluation and immediate management for a patient with elevated liver enzymes, increased serum creatinine, asterixis, and lethargy suggestive of acute hepatic encephalopathy with renal dysfunction?

Acute-on-Chronic Liver Failure with Hepatic Encephalopathy and Acute Kidney Injury

This patient has acute-on-chronic liver failure (ACLF) with hepatic encephalopathy (asterixis) and acute kidney injury, requiring immediate systematic workup for precipitating factors, ACLF grading, and urgent consideration for liver transplantation evaluation.

Immediate Diagnostic Assessment

Grade the ACLF severity using the CLIF-SOFA score to determine prognosis and guide management intensity. 1

• Cerebral failure: Asterixis indicates hepatic encephalopathy grade 1-2; grade III-IV encephalopathy (coma) defines cerebral organ failure 1
• Kidney failure: Creatinine ≥2.0 mg/dL defines renal organ failure; creatinine 1.5-1.9 mg/dL with another organ failure indicates ACLF grade Ib 1
• Liver failure: Bilirubin ≥12 mg/dL defines hepatic organ failure 1
• Additional organ systems: Assess coagulation (INR ≥2.5), circulation (need for vasopressors), and lungs (PaO₂/FiO₂ ≤200) 1

The ACLF grade determines mortality risk: No ACLF (<5% 28-day mortality), Grade Ia/Ib (14.6% mortality), Grade II (32% mortality), Grade III (78% mortality). 1, 2

Systematic Workup for Precipitating Factors

Every patient must undergo systematic evaluation for common precipitants, as identifying and treating these is critical for survival. 1, 3

Mandatory Initial Investigations

• Infection screening: Blood cultures, urinalysis with culture, diagnostic paracentesis with ascitic fluid cell count and culture, chest X-ray 1, 3
• Gastrointestinal bleeding: Complete blood count, assess for hemodynamic instability or recent bleeding history 1
• Alcohol-related hepatitis: AST/ALT ratio >2, recent heavy alcohol use 1
• Hepatitis B reactivation: HBV DNA level if HBsAg positive 1
• Hepatitis E superinfection: Anti-HEV IgM, particularly in endemic areas 1
• Drug-induced injury: Review all medications for hepatotoxins, nephrotoxins, or drugs causing encephalopathy 1, 4
• Electrolyte abnormalities: Sodium (hyponatremia occurs in 25-60% of cases), potassium 1, 3

82% of ACLF patients have multiple concomitant precipitating factors, and the number of precipitants is a major determinant of short-term mortality. 1, 3

Immediate Management Priorities

Hepatic Encephalopathy Management

Exclude other causes of altered mental status before attributing symptoms solely to hepatic encephalopathy. 5, 6

• Rule out intracranial hemorrhage, meningitis, metabolic encephalopathy (hypoglycemia, hyponatremia), drug intoxication, and uremic encephalopathy 4, 5
• Diuretic-induced hepatic encephalopathy must be considered if encephalopathy developed without other precipitating factors 1, 4
• Aluminum toxicity should be excluded in dialysis patients presenting with confusion and myoclonic jerks 4

Initiate bowel cleansing and non-absorbable antibiotics as the only evidence-based specific treatments for hepatic encephalopathy. 5

• Lactulose to achieve 2-3 soft bowel movements daily
• Rifaximin 550 mg twice daily
• Consider ICU admission for all patients with overt hepatic encephalopathy, particularly with ACLF 5

Acute Kidney Injury Management

Diagnose AKI using the ICA criteria: increase in serum creatinine ≥0.3 mg/dL within 48 hours OR increase ≥50% from baseline within 7 days. 1

Distinguish hepatorenal syndrome-AKI from other causes of AKI: 1

• Discontinue diuretics and nephrotoxic drugs immediately 1
• Expand volume with albumin 1 g/kg (maximum 100 g) to exclude prerenal azotemia 1
• Urinalysis to exclude intrinsic kidney disease (proteinuria, hematuria, casts) 1
• Renal ultrasound to exclude obstruction 1

If hepatorenal syndrome-AKI is diagnosed (creatinine ≥1.5 mg/dL without improvement after volume expansion), initiate vasoconstrictor therapy with albumin: 1, 7

• Terlipressin 1 mg IV every 4-6 hours PLUS albumin 1 g/kg day 1 (max 100 g), then 20-40 g/day 1, 7
• Escalate to terlipressin 2 mg every 4-6 hours if creatinine does not decrease ≥25% by day 3-4 1, 7
• Contraindications: SpO₂ <90%, active ischemia, creatinine >5 mg/dL 1, 7
• Monitor for ischemic complications (12% incidence) and respiratory failure (30% incidence, especially ACLF grade 3) 1, 7
• Alternative: Norepinephrine 0.5-3 mg/hour continuous infusion if terlipressin fails or is contraindicated 1, 7

Renal replacement therapy is indicated only as a bridge to liver transplantation in appropriate candidates with volume overload, severe electrolyte derangements, or uremia unresponsive to medical therapy. 1

Critical Monitoring and Supportive Care

Patients with ACLF grade 3 (≥3 organ failures) require ICU admission due to 78% 28-day mortality. 1, 2

• Monitor vital signs including pulse oximetry every 2-4 hours 7
• Daily serum creatinine, electrolytes, liver function tests 1
• Avoid nephrotoxic medications, particularly aminoglycosides 4
• Judicious fluid management to avoid volume overload and respiratory failure 7

Liver Transplantation Evaluation

All patients with refractory ascites, hepatorenal syndrome, or ACLF should be evaluated for liver transplantation urgently. 1

• Contact liver transplantation center immediately for patients with severe ACLF 1
• Hepatic encephalopathy grade 3-4 is a key indicator for transplant listing (King's College criteria) 1
• Achieving response to vasoconstrictor therapy improves post-transplant outcomes 7

Common Pitfalls to Avoid

• Do not attribute all symptoms to hepatic encephalopathy without excluding other causes of altered mental status 4, 5
• Do not continue diuretics once AKI is diagnosed 1
• Do not use terlipressin without concurrent albumin administration (response rate 25% vs 77% with combination) 7
• Do not delay escalation of terlipressin dose if creatinine reduction is <25% by day 3-4 1, 7
• Do not overlook multiple concomitant precipitating factors, as 82% of patients have more than one 3
• Do not administer excessive albumin, as volume overload increases respiratory failure risk 7